Drug Trial Radar · NCT03936049
Replication of the LEADER Diabetes Trial in Healthcare Claims
Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168,690
Actual
Start
Sep 22, 2017
Primary completion
Feb 18, 2021
Study completion Feb 18, 2021
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 3, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
- Diabetes
Interventions
LiraglutideDrug
Liraglutide dispensing claim is used as the exposure group
DPP-4 inhibitorDrug
DPP-4 inhibitor dispensing claim is used as the reference group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative hazard of composite outcome of Stroke, MI, and MortalityTime frame: Through study completion (a median of 154-188 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brigham And Women's Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.